Looking for Sentiment Analysis? Discover the most popular stocks on Reddit by using our Sentiment Tracker
Market Cap 354.26M P/E - EPS this Y 11.10% Ern Qtrly Grth -
Income -59.56M Forward P/E -9.21 EPS next Y 37.50% 50D Avg Chg -3.00%
Sales 181.41M PEG - EPS past 5Y - 200D Avg Chg 41.00%
Dividend N/A Price/Book 11.78 EPS next 5Y - 52W High Chg -16.00%
Recommedations 1.50 Quick Ratio 1.59 Shares Outstanding 149M 52W Low Chg 166.00%
Insider Own 3.91% ROA -7.04% Shares Float 141.88M Beta 1.31
Inst Own 41.68% ROE - Shares Shorted/Prior 11M/10.81M Price 2.58
Gross Margin 83.72% Profit Margin -32.83% Avg. Volume 1,188,125 Target Price 4.67
Oper. Margin -17.03% Earnings Date Nov 8 Volume 669,522 Change -4.09%
About Xeris Biopharma Holdings, Inc.

Xeris Biopharma Holdings, Inc., a biopharmaceutical company, engages in developing and commercializing therapies in Illinois. The company offers Gvoke, a ready-to-use liquid-stable glucagon for the treatment of severe hypoglycemia pediatric and adult patients; Keveyis, a therapy for the treatment of hyperkalemic, hypokalemic, and related variants of primary periodic paralysis; and Recorlev, a cortisol synthesis inhibitor proved for the treatment of endogenous hypercortisolemia in adult patients with Cushing's syndrome. It is also developing XP-8121, a once-weekly subcutaneous injection of levothyroxine that is in phase I clinical trial for the treatment of hypothyroidism; and non-aqueous XeriSol and XeriJect technologies for various therapies. The company was incorporated in 2005 and is headquartered in Chicago, Illinois.

Xeris Biopharma Holdings, Inc. News
11/26/24 Xeris to Participate in Piper Sandler 36th Annual Healthcare Conference
11/17/24 Analysts Expect Breakeven For Xeris Biopharma Holdings, Inc. (NASDAQ:XERS) Before Long
11/09/24 Xeris Biopharma Holdings Inc (XERS) Q3 2024 Earnings Call Highlights: Record Revenue Growth and ...
11/08/24 Xeris Biopharma (XERS) Q3 Earnings: Taking a Look at Key Metrics Versus Estimates
11/08/24 Xeris Biopharma (XERS) Reports Q3 Loss, Tops Revenue Estimates
11/08/24 Xeris Biopharma: Q3 Earnings Snapshot
11/08/24 Xeris Biopharma Reports Third Quarter 2024 Financial Results
10/31/24 Xeris Biopharma to Report Third Quarter 2024 Financial Results on November 8, 2024
10/09/24 Several Insiders Invested In Xeris Biopharma Holdings Flagging Positive News
10/04/24 Xeris Announces Inducement Grants Under NASDAQ Listing Rule 5635(c)(4)
05:22 AM Zevra Therapeutics (ZVRA) Moves 9.1% Higher: Will This Strength Last?
09/12/24 Xeris Biopharma Holdings, Inc. (NASDAQ:XERS) most popular amongst individual investors who own 53% of the shares, institutions hold 43%
08/22/24 Xeris to Participate in Upcoming Investor Conferences
08/08/24 Xeris Biopharma (XERS) Reports Q2 Loss, Tops Revenue Estimates
08/08/24 Xeris Biopharma: Q2 Earnings Snapshot
08/08/24 Xeris Biopharma Reports Second Quarter 2024 Financial Results
08/02/24 Earnings Preview: Amneal Pharmaceuticals (AMRX) Q2 Earnings Expected to Decline
08/01/24 Will Xeris Biopharma (XERS) Report Negative Earnings Next Week? What You Should Know
06:00 AM Xeris Biopharma to Report Second Quarter 2024 Financial Results on August 8, 2024
07/24/24 Xeris Biopharma (XERS) Now Trades Above Golden Cross: Time to Buy?
XERS Chatroom

User Image meistermell Posted - 12 hours ago

$ESPR $XERS

User Image ronday19200 Posted - 13 hours ago

$XERS

User Image SparkyReturns Posted - 13 hours ago

$XERS Santa is loading up the sleigh and Mrs. Claus is in the kitchen on her brokerage account smashing the buy button. Cheers! Happy Holidays!

User Image BarbarianTrades Posted - 14 hours ago

$XERS big money on the tape. Merry Christmas all!

User Image Ithaca2018 Posted - 23 hours ago

$XERS We shopped until we dropped! But nice to see us up after hours! It's a happy holiday season here in Chicago, Go XERS!

User Image BuyThisOne Posted - 1 day ago

$XERS Does anyone have knowledge of how the partnership option agreements work when a collab deal is struck? Are the financial terms of the agreement set at that point or is it negotiated when the company decides to move forward with the option? Do these options usually have an expiration date attached? Just thinking that if they don't have an answer from Regeneron by the March earnings call do they add the potential for an upfront payment in their 2025 earnings guidance or leave it out completely? These things could be pretty set in stone or could always be up in the air on the details. Any insight would be appreciated on this.

User Image SparkyReturns Posted - 1 day ago

$XERS Hmmm....

User Image meistermell Posted - 1 day ago

$ESPR $XERS

User Image hashemtrade Posted - 1 day ago

$XERS You're going to say the same about 5$ once it passes 4$ clown.

User Image Counselor53 Posted - 1 day ago

$XERS still in an ascending channel!

User Image Counselor53 Posted - 1 day ago

$XERS I believe in March XERS will be ready to report CF+ information, especially with the Recorlev growth. The CEO payout should be out of the way as well, opening the door to report CF+news. Runs with Dogs is right- many new investors this Spring once we see that- and that it will be consistent from this point on. I think we see double digits in 2025.

User Image RunsWithDogs Posted - 1 day ago

$XERS Cheeto, 3% is plummeting? Under average daily volume is Big Volume? Really? Brodman, When it does pass $4, $8, $12 are you switching sentiment, or just remaining bitter? Alon_R, If you have been a biotech investor for as long as I have, you know that XP-8121 reaching Phase III trials won't even create a blip on the chart when compared to going Cash Flow Positive. What this company needs is positive earnings, analyst visibility and volume! All the other catalysts are gravy...

User Image cheetohottaki Posted - 1 day ago

$XERS wow big volume and plummeting, thanks XERS, merry Xmas to you as you always seem to disappoint us leadership team, so congrats on that this year, we can always count on yall to put a damper on things when everyone is riding high and excited about your future, well done as always!

User Image Brodman Posted - 1 day ago

$XERS Same old XERS can't hold any increases....hasn't seen $4 in YEARS and it won't be happening anytime soon. Will see $2s before it ever sees $4s.

User Image Alon_R Posted - 1 day ago

$XERS Two major catalysts soon ("Here&Now") A)Very likely XP-8121 advancement to PH III announcement very soon. Even though nothing is a given, it based/rely on superb phase II clinical trial data, so it just makes sense. Reminder: Xeris mgmt(quite conservative mgmt), said that XP-8121 once approved, is very possible Blockbuster drug for Xeris. And if to be more accurate... For 20% upto 40% of Levo clientele(between $800M to $1.6B), XP-8121 SQ option will be very important once issued, maybe even crucial, in a matter to address a significant unmet need in hypothyroidism mgmt. So how much shifting of XP-8121 to phase III will be implemented in sp upside? I can't tell. But it's of course the drug that alongside Recorlev and Gvoke and some Xeriject deals, may take Xeris to 3 digits worth. B)II catalyst - Huge Recorlev growth (I think it's in a midst of a significant leap, that will lead Xeris to profitability very soon) Reminder: only ~15% of traded Bio comp. are profitabile.

User Image pascallambrecht Posted - 1 day ago

$XERS happy 2025 soon we need to go to 4/5 level

User Image NewEra8 Posted - 1 day ago

$XERS

User Image stockpsyche Posted - 2 days ago

$XERS beautiful 1 year chart. Congrats all. Company looks in great shape with more to come. Never got in, but always root for you. Some good folx on this board @Ithaca2018. 🥳

User Image Maissessap Posted - 2 days ago

$XERS All in all this is a very slow growing company. What is the reason to delay for so long the Levo P3???

User Image BuyThisOne Posted - 3 days ago

$XERS What's on deck you ask? 1.) 3 approved products, 2 of which are growing. 2.) Recorlev(for cushings and hypercortisolemia) grew $4.3 million Q2 to Q3 and may continue at this pace to $300 million plus. 3.) CF+ most likely in 2025 and maintained. 4.) 20%+ growth expected for at least next couple of years. 5.) Waiting on Regeneron to analyze stability studies for Xeriject on a couple molecules and potentially sign a platform partnership deal in 1st quarter. 6.) Gvoke should continue stealing market share from Baqsimi and grow to $200 million over the next 10 years. 7.) Once a week Levothyroxine shot Phase 3 clinical trial update in first half of 2025. 8.) Clinical trials for Amgen Tepezza Xeriject or Beta Bionics Xerisol Glucagon could get updates at any time. 9.) Another Xeriject/Xerisol deal could always be announced at any time as discussions are always taking place. SubQ market is expected to be $34 billion plus. Future is looking great. My price target is $4 for 2024 and $8 for 2025

User Image BuyThisOne Posted - 3 days ago

$XERS Only 10 weeks to go until earnings call for 2024. If they provide guidance for CF+, report record revenues, continued Recorlev growth and we land the Regeneron deal, where do you think that will put us? We would have to see at least $5 or $6 right? I would say at least $8 but I have been here too long to expect something reasonable.

User Image Ithaca2018 Posted - 3 days ago

$XERS Tomorrow our MVP NewEra8, rocks the field in Baltimore against the Steelers. A flock of beautiful Ravens flying in synchrony shall take the win!

User Image meistermell Posted - 4 days ago

$ESPR $XERS

User Image Bearly_Bullish_Trader Posted - 4 days ago

$XERS time to break $4.

User Image Aptos2024 Posted - 4 days ago

$XERS lol a 35 share trade A/H moves the needle 15 cents! Where is Sonnier!!!!

User Image simonig1 Posted - 4 days ago

$XERS @LurkerBoy The moon is just a pitstop. To the Stars! ;-0)

User Image LurkerBoy Posted - 4 days ago

$XERS To the moon!

User Image simonig1 Posted - 4 days ago

$XERS Here is today's chart about 20 minutes before the close. Bothe the short-term and long-term uptrends are intact!! Enjoy!!

User Image Nizmeister Posted - 4 days ago

$XERS from $amph q3 earnings report on glucagon sales: Glucagon sales decreased by 9% to $26.8 million due to increased competition in the market, reflecting a decline in unit shipments. we comin for dat ass.

User Image dave2ta Posted - 4 days ago

$XERS I just checked my Spotify Artist Page and saw Over 24 Thousand Streams for my Dave Evans Solo Vol. 1 Album.. they are from all over the world. It's very exciting to put your music out there and see it accepted and listened to... Here's a link to it on Spotify, please enjoy listening... 👍 https://open.spotify.com/album/2QOuw62TQkAa8ElNDeFkTa?si=Z2dELKPJSEyDQIaeUBT5lQ

Analyst Ratings
HC Wainwright & Co. Buy Aug 15, 24
HC Wainwright & Co. Buy May 31, 24
Piper Sandler Overweight May 10, 24
Oppenheimer Outperform Mar 28, 24
HC Wainwright & Co. Buy Mar 7, 24
HC Wainwright & Co. Buy Nov 13, 23
Piper Sandler Overweight Nov 10, 23
Craig-Hallum Buy Aug 28, 23
HC Wainwright & Co. Buy Aug 9, 23
Insider Trades Relationship Date Transactions Cost($) #Shares Value($) #Share Own SEC Form 4
Schmid John P. Director Director Nov 16 Buy 1.51 6,500 9,815 6,500 11/17/23
Shannon John Patrick Jr See Remarks See Remarks Nov 17 Buy 1.638 30,769 50,400 1,408,575 11/17/23
Edick Paul R See Remarks See Remarks Aug 09 Buy 2.3794 10,000 23,794 2,288,064 08/09/23